Black Diamond Therapeutics Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Black Diamond Therapeutics's estimated annual revenue is currently $14.4M per year.(i)
  • Black Diamond Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Black Diamond Therapeutics has 93 Employees.(i)
  • Black Diamond Therapeutics grew their employee count by -23% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.2M10%N/AN/A
#3
$4.2M2735%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$1.4M929%N/AN/A
#6
$235M255-31%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.3M340%N/AN/A
#10
$1.9M12-8%N/AN/A
Add Company

Black Diamond Therapeutics Inc. is a leading venture-backed biotechnology company focused on the discovery and development of precision medicines for cancer that are directed against a novel class of allosteric mutant oncogenes.

keywords:N/A

N/A

Total Funding

93

Number of Employees

$14.4M

Revenue (est)

-23%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Black Diamond Therapeutics News

2019-12-05 - Black Diamond Therapeutics Raises $85M in Series C Financing

Black Diamond Therapeutics, Inc., a Cambridge, Mass.-based precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, completed a Series C financing of $85m. The round was led by Boxer Capital of the Tavistock Group, with participat ...

2019-01-10 - Black Diamond Therapeutics Closes $85M Series B Financing

Black Diamond Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company developing next-generation precision medicines for cancer, completed an $85m Series B financing. The round was co-led by New Enterprise Associates and RA Capital Management, with participation from new investors Ne ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$11.2M93-4%N/A
#2
$23.3M9327%N/A
#3
$14.4M9352%N/A
#4
$12.1M938%N/A
#5
$13M93-13%N/A